Sort by
Refine Your Search
-
Category
-
Employer
-
Field
-
new and approved antiviral and immunomodulatory agents against hyperinflammatory and emerging viruses. By applying new and classical techniques from the fields of virology (including BSL-3/S3 work
-
interest in agentic AI, online learning and optimization, and applications in economics. The full-time positions (100%) are initially offered for two years, with the possibility of extension, depending
-
algorithms for large-scale or distributed training/Robustness, fairness, and personalization in multi-agent learning/Training efficiency and communication reduction/Distributed training of transformer models
-
-motivation and interest to learn new skills Great to have: Experience programming in Python, Julia, or C/C++ Experience with Mathematica Experience with finite element methods, agent-based simulations, and/or
-
software (e.g., LLM agents for finding and fixing bugs) Static and dynamic program analysis (e.g., to infer specifications) Test input generation (e.g., to compare the behavior of old and new code via
-
waves Agentic frameworks (e.g. LLMs with tool-use) for closed-loop idea generation for physics Other projects are certainly possible too. In general, we believe that building autonomous scientific systems
-
to reason about software (e.g., LLM agents for finding and fixing bugs)Static and dynamic program analysis (e.g., to infer specifications)Test input generation (e.g., to compare the behavior of old and new
-
CISPA Helmholtz Center for Information Security | Stuttgart, Baden W rttemberg | Germany | about 1 month ago
, efficient, and secure software. General areas of research include: Artificial intelligence to reason about software (e.g., LLM agents for finding and fixing bugs) Static and dynamic program analysis (e.g
-
Your Job: Develop AI pipelines that translate -omic signatures into dynamic model parameters Implement reinforcement-learning agents that optimise model performance Collaborate closely with
-
relevance. Your Tasks Antibody–Drug Conjugates (ADCs) are a rapidly advancing class of cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic agents. Upon